This difference in systemic versus locoregional administration of a 212Pb-mAb has also been observed with antibodies targeting the B7 homolog 3 protein (B7-H3, a.k.a. CD276), a regulatory immune protein overexpressed by various cancer types (Zhou and Jin 2021). The gene discussed is CD276; the disease is cancer.